Lukas Kasmann
Overview
Explore the profile of Lukas Kasmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
638
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kenndoff S, Nieto A, Guggenberger J, Taugner J, Mansoorian S, Kasmann L, et al.
Adv Radiat Oncol
. 2025 Feb;
10(2):101682.
PMID: 39896724
Purpose: The proliferation rates of non-small cell lung cancer (NSCLC) and associated radiation resistance highlight the potential of hypofractionated radiation therapy (hypoRT). However, radiation pneumonitis and esophagitis remain dose-limiting adverse...
2.
Neu M, Kahl K, Korner M, Walter R, Raab S, Jehs B, et al.
J Clin Med
. 2025 Jan;
13(24.
PMID: 39768473
: To analyze the results of interstitial (IRT) high-dose-rate (HDR) brachytherapy (BT) in the primary treatment of patients with unresectable superior sulcus tumors (SST) combined with external beam radiotherapy (EBRT)....
3.
Wurl M, Liubchenko G, Hu G, Schnurle K, Meyer S, Bortfeldt J, et al.
Phys Med Biol
. 2025 Jan;
70(2.
PMID: 39752881
Orthotopic tumor models in pre-clinical translational research are becoming increasingly popular, raising the demands on accurate tumor localization prior to irradiation. This task remains challenging both in x-ray and proton...
4.
Kasmann L, Nieto A, Rennollet R, Gurtner R, Oliinyk D, Augustin T, et al.
BMC Cancer
. 2024 Nov;
24(1):1477.
PMID: 39614234
Background: The prognosis of patients with anaplastic thyroid cancer (ATC) remains dismal. A small portion of patients experience longterm survival and need to be identified before treatment allocation. Survival scores...
5.
El-Marouk K, Kasmann L
Strahlenther Onkol
. 2024 Nov;
201(2):198-200.
PMID: 39545961
No abstract available.
6.
Huchel S, Grumt A, Keinki C, Buentzel J, Kasmann L, Huebner J
Integr Cancer Ther
. 2024 Oct;
23:15347354241293417.
PMID: 39468423
Background: The global burden of cancer continues to rise and complementary and alternative medicine (CAM) is attracting a lot of interest. However, quality of online information on CAM, particularly on...
7.
Zinn A, Kenndoff S, Holzgreve A, Kasmann L, Guggenberger J, Hering S, et al.
EJNMMI Rep
. 2024 Oct;
8(1):32.
PMID: 39375264
Background: Node-positive non-small cell lung cancers (NSCLCs) present a challenge for treatment decisions, particularly in patients ineligible for concurrent chemoradiotherapy (CRT) due to poor performance status and compromised lung function....
8.
Fink K, Forster M, Oettle M, Buttner M, Eze C, Kasmann L, et al.
J Cancer Res Clin Oncol
. 2024 Aug;
150(8):407.
PMID: 39212783
Introduction: Training of interdisciplinary clinical reasoning and decision-making skills, essential in daily clinical practice in oncological specialties, are still underrepresented in medical education. Therefore, at LMU University Hospital Munich, we...
9.
Feng Z, Yuan L, Ma L, Yu W, Kheir F, Kasmann L, et al.
Transl Lung Cancer Res
. 2024 Jul;
13(6):1346-1364.
PMID: 38973949
Background: Lung adenocarcinoma (LUAD) is among the most prevalent malignancies worldwide, with unfavorable treatment outcomes. Peptidyl-prolyl isomerase F () is known to influence the malignancy traits of tumor progression by...
10.
Wurschi G, Ruhle A, Domschikowski J, Trommer M, Ferdinandus S, Becker J, et al.
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38610958
Total neoadjuvant therapy (TNT) is an evolving treatment schedule for locally advanced rectal cancer (LARC), allowing for organ preservation in a relevant number of patients in the case of complete...